
==== Front
Obstet Med
Obstet Med
OBM
spobm
Obstetric Medicine
1753-495X
1753-4968
SAGE Publications Sage UK: London, England

10.1177/1753495X241263441
10.1177_1753495X241263441
Review Articles
Genetic issues in ICP
Hague WM “Bill”
Frise Charlotte
Lapinsky Stephen
https://orcid.org/0000-0002-9072-9131
Zöllner Julia 1
Williamson Catherine 2
Dixon Peter H 2
1 4919 University College London , London, UK
2 Imperial College London, London, UK
Julia Zöllner, University College London, 84-86 Chenies Mews, London WC1E 6HU, UK. Email: j.zollner@ucl.ac.uk
26 7 2024
9 2024
26 7 2024
17 3 Special Issue: A focus on intrahepatic cholestasis of pregnancy 157161
19 2 2024
5 6 2024
© The Author(s) 2024
2024
SAGE Publications
https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Intrahepatic cholestasis of pregnancy (ICP) is the commonest gestational liver disorder with variable global incidence. Genetic susceptibility, combined with hormonal and environmental influences, contributes to ICP aetiology. Adverse pregnancy outcomes linked to elevated serum bile acids highlight the importance of comprehensive risk assessment. ABCB4 and ABCB11 gene variants play a significant role in about 20% of severe ICP cases. Several other genes including ATP8B1, NR1H4, ABCC2, TJP2, SERPINA1, GCKR and HNF4A have also been implicated with ICP. Additionally, ABCB4 variants elevate the risk of drug-induced intrahepatic cholestasis, gallstone disease, gallbladder and bile duct carcinoma, liver cirrhosis and abnormal liver function tests. Genetic variations, both rare and common, intricately contribute to ICP susceptibility. Leveraging genetic insights holds promise for personalised management and intervention strategies. Further research is needed to elucidate variant-specific phenotypic expressions and therapeutic implications, advancing precision medicine in ICP management.

Intrahepatic cholestasis of pregnancy
genetics
genomics
pregnancy complications
typesetterts19
==== Body
pmcKey findings

Genetic susceptibility, hormonal and environmental factors contribute to the development of ICP.

Both common and rare genetic variations increase the susceptibility to ICP during pregnancy.

Homozygous variants in ABCB4 and ABCB11 (bile constituent transporters) cause severe cholestasis (PFIC), while heterozygous variants increase ICP risk and are thought to be involved in >20% of ICP cases.

Other genes including ATP8B1, NR1H4, TJP2, and ABCC2 have been implicated with lesser certainty to ICP.

Identifying susceptibility variants through testing can inform personalised management, holds promise for targeted therapies and prevention strategies.

Introduction

Intrahepatic cholestasis of pregnancy (ICP) is the commonest gestational liver disease. 1 The worldwide incidence varies widely (<1% to 4%) and may be explained by differences in susceptibility between ethnic groups as well as environmental factors.2-4 The highest incidence recorded worldwide was previously reported in the native Andean population in Chile (27.6%) 2 although this has fallen in recent years. In the UK, the incidence is 0.62% in women of European origin, and approximately twice as common in women of Indian (1.24%) and Pakistani (1.46%) origin. 5

ICP is characterised by pruritus presenting in the third trimester, elevated serum bile acids and abnormal tests of liver function. Adverse pregnancy outcomes, including preterm birth, fetal asphyxia, meconium-stained amniotic fluid and stillbirth, occur more commonly in pregnancies where maternal serum bile acid concentrations are ≥40 µmol.6,7 The recurrence risk is as high as 60–70% in subsequent pregnancies. 8 Recent evidence demonstrates a significant increase in stillbirth risk with serum bile acid concentrations ≥100 µmol from 35 weeks’ gestation. 9 A diagnosis of ICP is clinically significant due to its implications extending beyond the immediate pregnancy. These include an elevated risk of subsequent hepatobiliary disorders, encompassing cancer, immune-mediated conditions and cardiovascular diseases. 3 Furthermore, there is an increased prevalence of gallstone-related illnesses and a correlation between ICP and hepatitis C. 10

The role of genetics

The aetiopathogenesis of ICP is not well understood but genetic susceptibility, hormonal and environmental factors are believed to combine to cause ICP. Nutritional deficiencies in selenium and vitamin D, prevalent in specific regions and seasons, have been associated with increased ICP risk. 11 Additionally, the hormonal surge during pregnancy, particularly high oestrogen and progesterone levels, can trigger cholestasis in genetically predisposed individuals. 11 The genetic basis of ICP is supported by evidence of familial clustering,12,13 increased risk in first degree relatives 14 and population specific risk differences. 15 Thus far, the majority of genetic ICP studies have explored rare variation with minor allele frequencies <1%, as they thought to have larger effect sizes and more deleterious impact on protein function. Most studies have interrogated multiple European populations but are failing on diversity. Several genes have been implicated in the aetiopathogenesis of ICP including the ABCB4 (adenosine triphosphate-binding cassette (ATP), subfamily B, member 4) gene coding for the multidrug resistance 3 (MDR3) protein (a canalicular phospholipid translocator), and the ABCB11 (ATP-binding cassette, subfamily B, member 11) gene coding for the bile salt export pump (BSEP) (Figure 1). Homozygous variants or compound heterozygous variants in ABCB4 and ABCB11 can cause a spectrum of disease from moderate cholestasis to severe progressive familial intrahepatic cholestasis (PFIC), PFIC3 and PFIC2 respectively. Variants in ABCB4 and ABCB11 are involved in up to 25% of patients with severe ICP. 16 ABCB4 variants also increase the risk of developing drug-induced intrahepatic cholestasis, gallstone disease, gallbladder and bile duct carcinoma, liver cirrhosis and abnormal liver function tests. 17 Variants in several other canalicular transporters or their regulators are implicated in the pathogenesis of ICP, for example, ATP8B1 (ATPase phospholipid transporting 8B1), 18 NR1H4 (FXR, a principal bile acid sensor) gene19,20 and TJP2 (tight junction protein 2), 21 although supporting data are more limited. A recent study has demonstrated a possible role for ABCC2 (ATP-binding cassette sub-family C member 2) variants, which encodes a protein that is expressed in the canalicular (apical) part of the hepatocyte and functions in biliary transport 22 (Figure 1).

Figure 1. The role of canalicular transporters or their regulators implicated in the pathogenesis of ICP.

BA: bile acids; PC: phosphatidyl choline. Created with BioRender.com.

There is increasing evidence that common genetic variants (minor allele frequencies >5%) contribute to disease susceptibility, albeit to a much smaller degree than pathogenic variants. 23 A recent study, conducted in 1138 cases and 153,642 controls implicated 11 loci in liver-enriched genes and liver-specific cis-regulatory elements as contributing mechanisms to ICP susceptibility. For example, they found that a single missense coding variants in SERPINA1 (associated with cystic fibrosis liver disease), GCKR and HNF4A (both associated with hepatic metabolic homeostasis) had strong evidence for association, amongst other signals. 23 Therefore, both common and rare variants contribute to the genetic risk of ICP and can explain variability in disease.

ABCB4

The ABCB4 protein plays a crucial role in the transportation of phospholipids across cell membranes, specifically in the liver. Phospholipids in the bile function to solubilise bile acids, preventing them from causing harm. In addition, the phospholipid coat helps maintain the integrity of the bile canaliculi. Multiple heterozygous variants in the ABCB4 gene (chromosome 7, 7q21) have been reported in women with ICP16,21,22,24-40 (Table 1). There are reports that some variants or a combination of variants is associated with a more severe phenotype but no functional data is available to confirm this. 34 Additionally, common variants of the ABCB4 gene have been identified as genetic risk factors for the severe form of ICP in Sweden.22,39 The role of ABCB4 in ICP is further supported by its association with drug-induced cholestasis, where genetic variants of ABCB4 and ABCB11 have been implicated 41 including hormonal contraception. 42

Table 1. A summary of important rare and common genetic studies in ICP with a focus on ABCB4, ABCB11 and ATP8B1 genes.

Author	Study type	Number of participants	Gene	Interpretation	
Jacquemin 1999 24	Case study of a large consanguineous family	6	ABCB4	Identical heterozygous ABCB4 variant in all cases (NC_000007.14(NM_000443.4):c.1712del; (NP_000434.1):p.(Val571Aspfs*16))	
Dixon 2000 25	Case study	8	ABCB4	Heterozygous variant in 1 participant (NC_000007.14(NM_000443.4):c.1637C > A; (NP_000434.1):p.(Ala546Asp))	
Rosmorduc 2001 26	Case study	6	ABCB4	Heterozygous variant in 1 case (NC_000007.14(NM_000443.4):c.1327_1328insT; (NP_000434.1):p.(Gln443Leufs*5)), homozygous variant in 2 cases (NC_000007.14(NM_000443.4):c.959C > T; (NP_000434.1):p.(Ser320Phe))	
Lucena 2003 27	Case study	1	ABCB4	Heterozygous variant (NC_000007.14(NM_000443.4):c.1604G > C; (NP_000434.1):p.(Gly535Ala))	
Müllenbach 2003 28	Case study & Case-control	14	ABCB4	Heterozygous variant (NC_000007.14(NM_000443.4):c.449G > A; (NP_000434.1):p.(Arg150Lys))	
Eloranta 2003 43	Case-control study	57 cases & 115 controls	ABCB11	SNPs rs853782 (NC_000002.12(NM_003742.2):c.1331T > C; (NP_003733.2):p.(Val444Ala)) and rs473351 (NC_000007.14(NM_000443.4):c.1712T > A; (NP_000434.1):p.(Val571Glu)), (P = 0.04 and P = 0.02, respectively)	
Pauli-Magnus 2004 29	Case-control study	21 cases & 40 controls	ABCB4 & ABCB11	3 heterozygous variants (ABCB11, NC_000002.12(NM_003742.2):c.1772A > G; (NP_003733.2):p.(Asn591Ser); ABCB4, NC_000007.14(NM_000443.4):c.959C > T; (NP_000434.1):p.(Ser320Phe) and NC_000007.14(NM_000443.4):c.2285G > A; (NP_000434.1):p.(Gly762Glu))	
Floreani 2006 30	Case-control study	80 cases & 80 controls	ABCB4	3 heterozygous variants (NC_000007.14(NM_000443.4):c.1584G > C; (NP_000434.1):p.(Glu528Asp), NC_000007.14(NM_000443.4):c.1646G > A; (NP_000434.1):p.(Arg549His), NC_000007.14(NM_000443.4):c.1606G > C; (NP_000434.1):p.(Gly536Arg))	
Wasmuth 2007 39	Case-control study	52 cases & 52 controls	ABCB4 & ABCB11	ABCB4 haplotypes differed between the two groups (P = 0.019), but not in ABCB11	
Pasmant 2012 31	Case study	59 ICP/CIC cases	ABCB4	ABCB4 point or short insertion/deletion variants found in 27%	
Gotthardt 2008 32	Case study of a family with distal consanguinity	9	ABCB4	6 cases demonstrated heterozygous variant (NC_000007.14(NM_000443.4):c.2362C > T; (NP_000434.1):p.(Arg788Trp))	
Dixon 2009 33 *	Case-control study	491 cases & 261 controls	ABCB11	1.4% had ABCB11 variant. Common V444A association found	
Anzivino 2013 34	Case-control study	33 cases & 100 controls	ABCB4 & ABCB11	33% had a variant (5 ABCB4, 6 ABCB11), none in controls	
Dixon 2014 35	Case-control study	563 cases & 642 controls	ABCB4, ABCB11 &	Evidence of common polymorphisms (strongest association in rs2109505 NC_000007.14(NM_000443.4):c.711A > T; (NP_000434.1):p.(=) in ABCB4 and with rs7577650 NC_000002.12:g.169034700G > A in ABCB11)	
Dixon 2017 21	Cohort of ICP	147	ABCB11, ABCB4, & ATP8B1	14% had a variant (12 ABCB4, 4 ABCB11, 5 ATP8B1)	
Yeap 2018 40	Case study	5	ABCB4 & ABCB11	Heterozygous and homozygous variants in ABCB4 and ABCB11	
Truro 2020 16	Whole genome sequencing	310 severe early onset ICP cases	ABCB4 & ABCB11	20% of cases presented with variants	
Aydin 2020 18	Case study	25	ABCB4, ACBC11 & ATP8B1	Heterozygous variants observed ATP8B1 (n = 2), ABCB11 (n = 1) and ABCB4 (n = 7)	
Liu 2021 22	Whole exome sequencing	151 cases	44 ABC family transporter genes	ABCB4 (NC_000007.14(NM_000443.4):c.2123G > A; (NP_000434.1):p.(Trp708*), NC_000007.14(NM_000443.4):c.1580G > A; (NP_000434.1):p.(Gly527Glu) and NC_000007.14(NM_000443.4):c.1156A > G; (NP_000434.1):p.(Lys386Glu)), ABCB11 (NC_000002.12(NM_003742.2):c.3580C > T; (NP_003733.2):p.(Gln1194*), NC_000002.12(NM_003742.2):c.1814A > C ; (NP_003733.2):p.(Gln605Pro) and NC_000002.12(NM_003742.2):c.1765C > A; (NP_003733.2):p.(Leu589Met)), ABCC2 (NM_000392.4:r.(4025c > a); (NP_000383.1):p.(Ser1342Tyr))	
Müllenbach 2005 36	Case-control study	182 cases & 120 controls	ATP8B1	Two heterozygous variants (NM_005603.4:r.(208g > a) ; (NP_005594.1):p.(Asp70Asn) and NM_005603.4:r.(2599c > u); (NP_005594.1):p.(Arg867Cys)) in 3 cases	
Painter 2005 37	Case-control study	176 cases & 100 controls	ATP8B1	3% of cases had a variant versus none in controls	
Zöllner 2023 38	Whole exome sequencing	5000 volunteers – gene candidate approach	ABCB4, ABCB11 & ATP8B1	Novel variants identified in a British Bangladeshi and Pakistani cohort associated with ICP and cholestatic liver disease	
Dixon 2022 23 *	GWAS meta-analysis	1138 cases and 153,642 controls	11 loci identified	GCKR, ABCG5/8, ABCB11, SCARB2, ABCB1/4, CYP7A1, SERPINA1, ENPP7, TMEM147, SULT2A1, HNF4A	
AF: allele frequency; CIC: contraceptive-induced cholestasis; GWAS: genome wide association studies; ICP: intrahepatic cholestasis of pregnancy; *common variation studies.

To date, there are 102 reported variants associated with ICP in the Clinvar database (https://www.ncbi.nlm.nih.gov/clinvar/; a freely available, public archive of human genetic variants and interpretations of their significance to disease). Of those 11 are considered pathogenic and 4 as likely pathogenic. 44

ABCB11

ABCB11 actively transports conjugated bile acids from hepatocytes into the bile canaliculi. This unidirectional pump mechanism operates against a concentration gradient, efficiently clearing the cytoplasm of potentially toxic bile acids and funnelling them into the digestive tract. A number of heterozygous variants in the ABCB11 gene (chromosome 2, 2q24) have been implicated in the development of ICP16,18,21,22,29,33-35,38-40,43 (see Table 1). Despite sometimes being classified as benign the ABCB11 variant V444A (RefSeq: NP_003733.2) paints a puzzling picture. Evidence suggests it may contribute to an increased risk of ICP, progression of hepatitis C disease and even drug-induced liver injury.29,33 The exact mechanisms through which it exerts these effects, however, remain not understood. This apparent disconnect between classification and observed associations underscores the complexity of our understanding of genetic variants and their diverse clinical implications.33,45 In Clinvar, a smaller number of variants (n = 12) have been reported in ABCB11, of which four are pathogenic, and five are considered likely pathogenic.

ATP8B1 (FIC-1)

The lack of ATP8B1 is associated with an asymmetry of phospholipids in the canalicular membrane, decreasing the bile secretion capacity of the liver. Although the ATP81B gene (chromsome 18, 18q21.31) product is not directly involved in the bile acid transport, it may affect the bile acid transporters like BSEP and their functions, contributing to the disease aetiopathogenesis. Although there is less evidence of the implications of the ATP8B1 gene in the involvement of ICP there have been several studies published that have demonstrated heterozygous variants associated with ICP18,21,36-38 (see Table 1). In Clinvar out of 19 there is only 1 likely pathogenic and one pathogenic variant reported.

Conclusion

Common and rare genetic variations play a complex and interdependent role in the development of ICP. While common variants increase susceptibility to the condition by two- to three-fold, rare variants are believed to cause ICP. Both types of variations can interact with environmental and hormonal factors. There is a clear role for the use of genetic information to improve diagnosis, personalise care and implement prevention strategies. Additional research is needed to determine if specific genetic variants or combinations of variations lead to more severe phenotypes or if other factors contribute to adverse outcomes. Identifying genetic susceptibility through testing can help to inform personalised management strategies, including early intervention after pregnancy for women affected by ICP but also their relatives. Understanding the functional consequences of specific variants can also pave the way for targeted therapies in the future.

Contributorship: JZ wrote the first draft of the article. CW and PD contributed revisions to the draft and gave final approval of the final draft to be published.

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: CW consults for Mirum and GSK.

Funding: The authors received no financial support for the research, authorship, and/or publication of this article.

Guarantor: Peter H Dixon.

ORCID iD: Julia Zöllner https://orcid.org/0000-0002-9072-9131
==== Refs
References

1 Williamson C Geenes V . Intrahepatic cholestasis of pregnancy. Obstet Gynecol 2014; 124 : 120–133.24901263
2 Reyes H Gonzalez MC Ribalta J , et al. Prevalence of intrahepatic cholestasis of pregnancy in Chile. Ann Intern Med 1978; 88 : 487–493.637428
3 Wikström Shemer E Marschall HU Ludvigsson JF , et al. Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12-year population-based cohort study. BJOG 2013; 120 : 717–723.23418899
4 Bull LN Hu D Shah S , et al. Intrahepatic cholestasis of pregnancy (ICP) in U.S. Latinas and Chileans: clinical features, ancestry analysis, and admixture mapping. PLoS One 2015; 10 : e0131211.
5 Geenes V Williamson C . Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009; 15 : 2049–2066.19418576
6 Geenes V Chappell LC Seed PT , et al. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatology 2014; 59 : 1482–1491.23857305
7 Glantz A Marschall HU Mattsson LA . Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology 2004; 40 : 467–474.15368452
8 Hepburn IS Schade RR . Pregnancy-associated liver disorders. Dig Dis Sci 2008; 53 : 2334–2358.18256934
9 Ovadia C Seed PT Sklavounos A , et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet 2019; 393 : 899–909.30773280
10 Marschall H-U Wikström Shemer E Ludvigsson JF , et al. Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population-based cohort study. Hepatology 2013; 58 : 1385–1391.23564560
11 Dixon PH Williamson C . The pathophysiology of intrahepatic cholestasis of pregnancy. Clin Res Hepatol Gastroenterol 2016; 40 : 141–153.26823041
12 Reyes H Ribalta J González-Cerón M . Idiopathic cholestasis of pregnancy in a large kindred. Gut 1976; 17 : 709–713.976812
13 Holzbach RT Sivak DA Braun WE . Familial recurrent intrahepatic cholestasis of pregnancy: a genetic study providing evidence for transmission of a sex-limited, dominant trait. Gastroenterology 1983; 85 : 175–179.6852450
14 Eloranta ML Heinonen S Mononen T , et al. Risk of obstetric cholestasis in sisters of index patients. Clin Genet 2001; 60 : 42–45.11531968
15 Andress EJ Nicolaou M Romero MR , et al. Molecular mechanistic explanation for the spectrum of cholestatic disease caused by the S320F variant of ABCB4. Hepatology 2014; 59 : 1921–1931.24806754
16 Turro E Astle WJ Megy K , et al. Whole-genome sequencing of patients with rare diseases in a national health system. Nature 2020; 583 : 96–102.32581362
17 Stättermayer AF Halilbasic E Wrba F , et al. Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults. J Hepatol 2020; 73 : 651–663.32376413
18 Aydın GA Özgen G Görükmez O . The role of genetic mutations in intrahepatic cholestasis of pregnancy. Taiwan J Obstet Gynecol 2020; 59 : 706–710.32917322
19 Davit-Spraul A Gonzales E Jacquemin E . NR1H4 Analysis in patients with progressive familial intrahepatic cholestasis, drug-induced cholestasis or intrahepatic cholestasis of pregnancy unrelated to ATP8B1, ABCB11 and ABCB4 mutations. Clin Res Hepatol Gastroenterol 2012; 36 : 569–573.23142591
20 Van Mil SW Milona A Dixon PH , et al. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 2007; 133 : 507–516.17681172
21 Dixon PH Sambrotta M Chambers J , et al. An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy. Sci Rep 2017; 7 : 11823.28924228
22 Liu X Lai H Xin S , et al. Whole-exome sequencing identifies novel mutations in ABC transporter genes associated with intrahepatic cholestasis of pregnancy disease: a case-control study. BMC Pregnancy Childbirth 2021; 21 : 110–110.33546617
23 Dixon PH Levine AP Cebola I , et al. GWAS meta-analysis of intrahepatic cholestasis of pregnancy implicates multiple hepatic genes and regulatory elements. Nat Commun 2022; 13 : 4840.35977952
24 Jacquemin E Cresteil D Manouvrier S , et al. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 1999; 353 : 210–211.9923886
25 Dixon PH Weerasekera N Linton KJ , et al. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet 2000; 9 : 1209–1217.10767346
26 Rosmorduc O Poupon R Hermelin B . MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 2001; 120 : 1459–1467.11313316
27 Lucena J-F Herrero JI Quiroga J , et al. A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. Gastroenterology 2003; 124 : 1037–1042.12671900
28 Müllenbach R Linton KJ Wiltshire S , et al. ABCB4 gene sequence variation in women with intrahepatic cholestasis of pregnancy. J Med Genet 2003; 40 : e70–e70.
29 Pauli-Magnus C Lang T Meier Y , et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenet 2004; 14: 91–102.
30 Floreani A Carderi I Paternoster D , et al. Intrahepatic cholestasis of pregnancy: three novel MDR3 gene mutations. APT 2006; 23 : 1649–1653.
31 Pasmant E Goussard P Baranes L , et al. First description of ABCB4 gene deletions in familial low phospholipid-associated cholelithiasis and oral contraceptives-induced cholestasis. Eur J Hum Genet 2012; 20 : 277–282.21989363
32 Gotthardt D Runz H Keitel V , et al. A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults. Hepatology 2008; 48 : 1157–1166.18781607
33 Dixon PH van Mil SW Chambers J , et al. Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut 2009; 58 : 537–544.18987030
34 Anzivino C Odoardi MR Meschiari E , et al. ABCB4 And ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population. Dig Liver Dis 2013; 45 : 226–232.23022423
35 Dixon PH Wadsworth CA Chambers J , et al. A comprehensive analysis of common genetic variation around six candidate loci for intrahepatic cholestasis of pregnancy. Am J Gastroenterol 2014; 109 : 76–84.24366234
36 Müllenbach R Bennett A Tetlow N , et al. ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy. Gut 2005; 54 : 29.
37 Painter JN Savander M Ropponen A , et al. Sequence variation in the ATP8B1 gene and intrahepatic cholestasis of pregnancy. Eur J Hum Genet 2005; 13 : 435–439.15657619
38 Zöllner J Finer S Linton KJ , et al. Rare variant contribution to cholestatic liver disease in a South Asian population in the United Kingdom. Sci Rep 2023; 13 : 8120.37208429
39 Wasmuth HE Glantz A Keppeler H , et al. Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene. Gut 2007; 56 : 265–270.16891356
40 Yeap SP Harley H Thompson R , et al. Biliary transporter gene mutations in severe intrahepatic cholestasis of pregnancy: diagnostic and management implications. J Gastroenterol Hepatol 2019; 34 : 425–435.29992621
41 Pauli-Magnus C Meier PJ Stieger B . Genetic determinants of drug-induced cholestasis and intrahepatic cholestasis of pregnancy. Semin Liver Dis 2010; 30 : 147–159.20422497
42 Jirsa M Bronský J Dvořáková L , et al. ABCB4 mutations underlie hormonal cholestasis but not pediatric idiopathic gallstones. World J Gastroenterol 2014; 20 : 5867–5874.24914347
43 Eloranta ML Häkli T Hiltunen M , et al. Association of single nucleotide polymorphisms of the bile salt export pump gene with intrahepatic cholestasis of pregnancy. Scand J Gastroenterol 2003; 38 : 648–652.12825874
44 Landrum MJ Lee JM Benson M , et al. Clinvar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res 2017; 46 : D1062–D1067.
45 Ali I Khalid S Stieger B , et al. Effect of a common genetic variant (p.V444A) in the bile salt export pump on the inhibition of bile acid transport by cholestatic medications. Mol Pharm 2019; 16 : 1406–1411.30608704
